Nursing Elites

1. A healthcare provider is reviewing the health care record of a client who is asking about conjugated equine estrogens. The healthcare provider should inform the client this medication is contraindicated in which of the following conditions?

• A. Atrophic vaginitis
• B. Dysfunctional uterine bleeding
• C. Osteoporosis
• D. Thrombophlebitis

Correct answer: D

Rationale: Conjugated equine estrogens are contraindicated in individuals with a history of thrombophlebitis due to the increased risk of thrombotic events associated with estrogen use. Thrombophlebitis is a condition characterized by inflammation and blood clot formation in the veins, and estrogen therapy can exacerbate this condition, leading to serious complications such as deep vein thrombosis. Therefore, caution is advised when considering estrogen therapy in clients with a history of thrombophlebitis to prevent adverse outcomes. Choices A, B, and C are not contraindications for conjugated equine estrogens. Atrophic vaginitis and dysfunctional uterine bleeding may actually be conditions for which estrogen therapy is indicated. Osteoporosis can also be managed with estrogen therapy in certain cases to help prevent bone density loss.

2. A healthcare provider is providing instructions to the parent of an adolescent client who has a new prescription for Albuterol, PO. Which of the following instructions should the healthcare provider include?

• A. You should not use this medication for an acute asthma attack.'
• B. Tremors may be an adverse effect of this medication.'
• C. Long-term use of this medication can lead to hyperglycemia.'
• D. This medication can inhibit skeletal growth.'

Correct answer: B

Rationale: Tremors may occur as a result of excessive stimulation of beta2 receptors in skeletal muscles when using Albuterol. It is important to educate the parent about potential adverse effects to ensure proper monitoring and management of the adolescent client's medication regimen.

3. A healthcare professional is caring for a client who has a new prescription for Lisinopril. Which of the following laboratory values should the professional monitor?

• A. Serum potassium
• B. Serum sodium
• C. Serum calcium
• D. Serum magnesium

Correct answer: A

Rationale: Lisinopril is an ACE inhibitor that can cause hyperkalemia by reducing the excretion of potassium in the kidneys. Monitoring serum potassium levels is essential to prevent complications such as cardiac arrhythmias. Therefore, the healthcare professional should closely monitor the client's serum potassium levels when they are on Lisinopril. Choices B, C, and D are incorrect because Lisinopril primarily affects potassium levels due to its mechanism of action as an ACE inhibitor. Serum sodium, calcium, and magnesium levels are not typically affected by Lisinopril in the same way as potassium.

4. A healthcare professional is preparing to administer IV Vancomycin to a client who has a systemic infection. Which of the following actions should the healthcare professional take?

• A. Administer the medication rapidly over 15 minutes.
• B. Monitor the client for hypertension during infusion.
• C. Administer a test dose before the full dose.
• D. Monitor the client for Red Man Syndrome.

Correct answer: D

Rationale: The correct action for the healthcare professional is to monitor the client for Red Man Syndrome. Red Man Syndrome is a common adverse reaction to Vancomycin characterized by flushing, rash, and hypotension. It is important to monitor the client for these symptoms to intervene promptly if they occur.

5. Which of the following is considered a class IA Sodium Channel blocker?

• A. Mexiletine
• B. Amiodarone
• C. Quinidine
• D. Procainamide

Correct answer: D

Rationale: Procainamide is a class IA antiarrhythmic drug that acts as a sodium channel blocker by blocking fast sodium channels. Mexiletine is a class IB antiarrhythmic drug, not class IA. Amiodarone is a class III antiarrhythmic, and Quinidine is a class IA antiarrhythmic but not a sodium channel blocker.

Similar Questions